Unveiling 10 Analyst Insights On Integra Lifesciences
Unveiling 10 Analyst Insights On Integra Lifesciences
揭示10位分析师对英特格拉生命科学的见解
A comprehensive...In the last three months, 10 analysts have published ratings on Integra Lifesciences (NASDAQ:IART), offering a diverse range of perspectives from bullish to bearish.
在过去的三个月中，有10位分析师发布了对Integra Lifesciences（纳斯达克：IART）的评级，提供了从看好到看淡的多样化观点。
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他们最近的评级概况，突出了过去30天内情绪的变化，并将其与之前的月份进行了比较。
Analysts have recently evaluated Integra Lifesciences and provided 12-month price targets. The average target is $25.1, accompanied by a high estimate of $35.00 and a low estimate of $16.00. Experiencing a 7.41% decline, the current average is now lower than the previous average price target of $27.11.
分析师最近对英特格拉生命科学进行了评估，并提供了12个月的价格目标。平均目标价为25.1美元，最高估值为35.00美元，最低估值为16.00美元。当前平均价格目标下降了7.41%，目前的平均价格比之前的27.11美元的目标价格更低。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析师评级：详细剖析
A comprehensive...
最近...
登录免费看全文
登录/注册
资讯热榜
更新时间